{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:09:40Z","timestamp":1789088980886,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medj.2026.101227","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:40:27Z","timestamp":1786722027000},"page":"101227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?"],"prefix":"10.1016","volume":"7","author":[{"given":"Giulia","family":"Orsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101227_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","author":"O\u2019Reilly","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101227_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101227_bib3","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101227_bib4","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A Randomized Phase III Study of Fluorouracil\/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101227_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study","volume":"42","author":"De La Fouchardi\u00e8re","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101227_bib6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1056\/NEJMe2600517","article-title":"Advances in RAS Therapeutics for Pancreatic Cancer","volume":"394","author":"Der","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101227_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116683","article-title":"Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I\/II randomized NAPAN trial","volume":"239","author":"Gehrels","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2026.101227_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.dld.2024.06.025","article-title":"Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life","volume":"57","author":"Reni","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.medj.2026.101227_bib9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/cancers18111844","article-title":"Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance","volume":"18","author":"Ramesh","year":"2026","journal-title":"Cancers (Basel)"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026002308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:49:00Z","timestamp":1789087740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026002308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666634026002308"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101227","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind?","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101227"}}